Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gasdermin D short hairpin RNA (shGSDMD) is a research-grade RNA interference (RNAi) tool designed to specifically silence the expression of the gasdermin D (GSDMD) gene. GSDMD is a critical executioner of pyroptosis, a pro-inflammatory form of programmed cell death. Upon activation by inflammatory caspases, the N-terminal fragment of GSDMD oligomerizes to form large pores in the plasma membrane, leading to cell swelling, lysis, and the release of cytosolic contents such as IL-1β and LDH. In preclinical research, particularly in models of endometrial carcinoma, shGSDMD is utilized to investigate the role of pyroptosis in tumor biology and to evaluate the impact of GSDMD depletion on membrane integrity and inflammatory signaling. By reducing GSDMD levels, researchers can demonstrate the inhibition of pore formation and the subsequent reduction in pyroptotic cell death markers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gasdermin D short hairpin RNA.